Catalent Pharma invests $5m in drug development center of excellence to expand its hot melt extrusion capabilities for formulation and drug delivery method optimization.
A drug is only as effective as its delivery system, and the advent of new molecules and new innovations have to be matched by enhanced delivery and containment methods, suggests West Pharma exec.
Haselmeier to provide assembly, labeling, and packaging services for its drug-device combination products following recent permission given to Germany-site.
US FDA Psychopharmacologic Drug Advisory Committee recommends Spravato, an intranasal form of esketamine, for approval based on its favorable benefit-risk profile.
As complex drugs see little competition, the FDA will distribute guidelines to increase approvals of generic medicines for ‘economic stability’ and to bring affordable drugs to patients.
AstraZeneca and Aptamer Group will collaborate to leverage Aptamer’s platform for targeted delivery of oligonucelotides to the kidney for therapeutic development.
This week in-PharmaTechnologist attended AAPS PharmSci360 in Washington, D.C. where discussions and thought-provoking ideas bounced across sessions – here, we highlight some of the most significant.
In this first part of a two-part investigation, we look at how NDMA receptor antagonists, such as ketamine, could be poised to make a breakthrough in the treatment of depression – an area where the pharma industry has struggled to identify new targets...
A study at Washington University in St. Louis has shown a new way to deliver drugs to the brainstem in a non-invasive administration: microbubbles and ultrasound.
Partnering and collaborating to advance drug delivery innovation is essential, now more than ever, say industry experts from Boehringer-Ingelheim and Merck.
Xenetic Biosciences says success for Shire’s haemophilia A candidate SHP656 will validate its PolyXen drug delivery technology platform and could net the firm up to $100m.
Researchers suggest targeted nanosystem drug delivery could be the key to crossing gastrointestinal tract and blood-brain barriers – a prevailing issue with oral medications.
Researchers studying chemical reactions in urine have created an adhesive gel for drug delivery applications that they say is cheaper and easier to make than hydrogel-based carriers.
In an exclusive Q&A, nanoparticle pioneer Kathryn Whitehead wishes industry would invest more in delivery vehicles and predicts Alnylam will be first to commercialise an siRNA therapeutic.
More cancer drugs are going to be delivered using nanoparticles according to Frost & Sullivan, which says research breakthroughs are going to drive adoption of such technologies.
Catalent has urged industry and academia to share knowledge about delivery technologies to help improve drug efficacy as it signs a deal to develop ADHD treatments for Cingulate.
An increased trend in dealmaking for targeted drug delivery last year will continue to drive partnerships in 2014, according to a pharmaceutical partnering expert.
A drug delivery technology that ‘shuttles’ molecules across the blood-brain-barrier could have major implications in developing drugs for disorders such as Alzheimer's and Parkinson’s disease, Roche says.
Many physicians would switch migraine patients from oral treatments if the same drugs were available as a nasal inhalation, topical, or transdermal patch according to a new report.
Having been granted a series of patents, MedSpray’s ‘patch-in-a-can’ spray-on-film technology can offer dermatological, topical and transdermal drug delivery, says MedPharm.
Good ideas in drug delivery will continue to attract investment though the increasing cost of clinical trials does pose a difficulty according to MIT Professor Robert Langer.
Scientists at UCF (University of Central Florida) believe they have found a simpler and more efficient way to mass produce the structured nanoparticles used for drug delivery and production.
Drug regulators and the biomanufacturing industry need to embrace drug delivery via the skin to solve solubility problems with peptides and proteins, according to Across Barriers’ Udo Bock.
Quotient has stressed the importance of screening prototype formulations early in the development process to ensure efficient drug delivery in later phases.
in-PharmaTechnologist presents its round-up of the latest drug delivery research developments in the pharmaceutical world, including tumour targeting peptides and lipid nanoparticle drug-delivery technology.
A device developed at the Joseph Fourier University could be used to power drug delivery technologies and medical implants using energy created in vivo within the next decade, say researchers.